Newsletter · · Ashutosh Agarwal

Curium Takes Out Lantheus in an 8 Billion Dollar Radiopharma Deal - The Biotech Patent Cliff & M&A - Week of August 28, 2026

The Biotech Patent Cliff & M&A for the week ending August 28, 2026. Curium agreed to take Lantheus private for $102.50 a share in cash plus a contingent value right worth up to $12 more, a roughly $8 billion deal that landed days after the FDA cleared Lantheus's TauClarify Alzheimer's imaging agent, and the structure is a clean lesson in how a clean balance sheet and a milestone payout let a buyer pay a premium without overpaying today.

The Biotech Patent Cliff & M&A

Week of August 28, 2026: Curium Takes Out Lantheus in an 8 Billion Dollar Radiopharma Deal

TL;DR

  • The one deal that matters: Curium is buying Lantheus (LNTH) for up to roughly $8 billion. $102.50 a share in cash, plus a contingent value right worth up to $12 more, an IOU that only pays out if certain drug-sales targets are hit. It is a clean case study in how buyers bridge a price gap without overpaying today.
  • The structure is the lesson, not the headline number. A debt-light balance sheet is what let someone else step in and pay up, and the milestone payout is what let the buyer reach on headline value while pushing part of the bill into the future.
  • A caution on sourcing. The episode carrying this week's pharma content is an AI-generated commentary show. One of its segments, on Eli Lilly, jumbled events from 2009, 2017 and this past spring into a single "all in one week" story. The bad parts were checked and thrown out, and only what holds up is kept below.

What's new

Curium is taking Lantheus private for up to about $8 billion, and the structure is the story

This is the one genuinely on-theme M&A discussion the tape delivered, on Telltales' Weekend Update - W2634. A note on the source: Telltales is an independent, AI-generated market-commentary podcast, not a company insider and not a sell-side desk. Its deal facts on this one check out, and they were verified separately before being run with here.

Here is the deal in plain terms. Lantheus makes radiopharmaceuticals, drugs with a tiny radioactive tag attached, used to light up disease on a scan or to deliver radiation straight to a tumor. Curium, a large private radiopharmaceutical company, agreed to buy it for $102.50 per share in cash, plus a contingent value right (CVR) worth up to $12 more, bringing the maximum to $114.50. A CVR is essentially a promise of extra cash later, paid only if specific milestones are hit. Here they are tied to sales targets across Lantheus's prostate-cancer imaging, neurology imaging, and heart-imaging (Definity) franchises. Total potential value: roughly $8 billion, with the deal expected to close in the first half of 2027.

The timing rhymes with a big product win. The takeout landed within days of the FDA approving TauClarify, Lantheus's brain-scan agent that highlights the tau protein tangles doctors look for when evaluating someone for Alzheimer's disease. When the agreement was signed, Lantheus pulled its own forecast, which as the podcast put it is "what a company does when the forecast stops being its decision."

Why the structure is worth your time

The hosts' framing was sharp, and it generalizes to every deal in this cycle. Their line:

"The multiple tells you what the market will pay for the cash flow. The leverage tells you who gets to decide what happens to it."

Their point: Lantheus trades around 12 times its trailing free cash flow with essentially no debt, "12 times trailing free cash flow at one turn of leverage, got itself a buyer at a premium." A clean balance sheet is what let someone else step in and pay up, with Curium paying roughly 15 times that trailing cash flow to take the whole thing out. A heavily indebted company, by contrast, has to be its own buyer, because no one else can carry the load. The CVR does the rest of the work: it lets Curium pay a full price today while pushing part of the bill into the future, payable only if the assets deliver. Cash up front, upside shared, risk split. That is the template.

The merger-arbitrage tell

Lantheus still trades below the $102.50 cash offer. That is not skepticism about the deal, it is simply the math of a long wait. With a close not expected until the first half of 2027, the gap between today's price and the payout is the cost of holding money for a year and a half. As the podcast noted, "a 2027 close will do that."

A word on the Eli Lilly segment, and why most of it was left out

The same episode ran a segment framing Lilly as having done four big things "in the same seven days": a Zyprexa guilty plea with a roughly $800 million payment, three vaccine and infectious-disease acquisitions for about $3.8 billion, a $50 million CureVac mRNA cancer partnership, and a raised full-year revenue guide. Each one was checked. Only the guidance raise is genuinely current: Lilly did lift its 2026 revenue outlook to roughly $85 billion to $87 billion, on continued Mounjaro and Zepbound strength. The rest is a jumble. The Zyprexa plea is from 2009, the CureVac mRNA deal is from 2017 (and was terminated in 2020), and the three vaccine bolt-ons were actually announced back in May 2026. This is exactly the failure mode to worry about with an AI-generated show, and it is why the claims get verified before they get forwarded.

The names in play

  • Lantheus (LNTH) is the week's one real name. A profitable, debt-light radiopharmaceutical maker getting taken out at $102.50 cash plus up to $12 in milestone-based CVRs, days after a fresh FDA approval (the TauClarify Alzheimer's imaging agent). The thing to watch is the arbitrage gap: the stock sits below the cash offer purely because the close is a year and a half out.
  • Eli Lilly (LLY) is included only to set the record straight. The sole current item is a raised 2026 revenue guide to roughly $85 billion to $87 billion. The rest of this week's podcast framing on Lilly does not hold up, as noted above.

Read-throughs

  • Radiopharmaceuticals are quietly a hot M&A corner. The Lantheus takeout is another data point that imaging and targeted-radiation assets, profitable, cash-generative, with clear product catalysts like an FDA nod, are exactly what strategic and private buyers want right now.
  • The CVR is doing real work in this cycle. Buyers are willing to reach on headline value as long as part of the price is contingent on delivery. Expect the structure to show up again wherever a seller's asking price depends on a product ramp the buyer cannot yet underwrite.
  • Balance sheet quality decides who is the buyer and who is the target. The cleaner the leverage, the more optionality a board has when someone comes knocking. That is the transferable lesson from a deal in an unglamorous corner of the market.

What changed

The through-line from last week to this one holds: last week's takeaway was that a soaring stock price is dealmaking currency and that there would be plenty more activity. This week delivered one more deal to that pile, just in radiopharma diagnostics rather than the headline oncology names.